Catalyst Pharmaceutical CPRX Non Cash Change In Right Of Use Asset
Non Cash Change In Right Of Use Asset at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept cprx:NonCashChangeInRightOfUseAsset.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's non cash change in right of use asset.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's non cash change in right of use asset?
- Catalyst Pharmaceutical (CPRX) reported non cash change in right of use asset of $77K in Q1 2026.
- How has Catalyst Pharmaceutical's non cash change in right of use asset changed year-over-year?
- Catalyst Pharmaceutical's non cash change in right of use asset increased by 6.9% year-over-year, from $72K to $77K.
- What is the long-term trend for Catalyst Pharmaceutical's non cash change in right of use asset?
- Over 3 years (2022 to 2025), Catalyst Pharmaceutical's non cash change in right of use asset has grown at a 6.1% compound annual growth rate (CAGR), from $247K to $295K.
- What does non cash change in right of use asset mean?
- This reflects the non-cash adjustments related to the amortization or impairment of right-of-use assets recognized under lease accounting standards. It serves as a reconciliation item to adjust net income for lease-related expenses that do not involve immediate cash outflows. Tracking this helps analysts distinguish between operational cash expenses and accounting-driven lease valuations.